Erratum: Direct Correlation Between Ligand-Induced α-Synuclein Oligomers and Amyloid-like Fibril Growth (Scientific Reports (2015) 5 (10422) DOI: 10.1038/srep10422);Direct correlation between ligand-induced α-synuclein oligomers and amyloid-like fibril growth

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Nors Perdersen, Martin ^a   Foderà, Vito ^a   Horvath, Istvan ^b   Van Maarschalkerweerd, Andreas ^a   Nørgaard Toft, Katrine ^a   Weise, Christoph ^b   Almqvist, Fredrik ^b   Wolf Watz, Magnus ^b   Wittung Stafshede, Pernilla ^b   Vestergaard, Bente ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2-HYDROXYPYRIDINE; ALPHA SYNUCLEIN; AMYLOID; AMYLOID PROTEIN; LIGAND; PYRIDONE DERIVATIVE;

ALZHEIMER DISEASE; CHEMISTRY; HUMAN; METABOLISM; PARKINSON DISEASE; PATHOLOGY; PROTEIN SECONDARY STRUCTURE; PROTEINOSIS;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID; AMYLOIDOGENIC PROTEINS; HUMANS; LIGANDS; PARKINSON DISEASE; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN STRUCTURE, SECONDARY; PYRIDONES;

EID: 84930659235     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15692     Document Type: Erratum

References (31)

1. Spillantini MG et al. ?-Synuclein in Lewy bodies. Nature 388, 839-840 (1997).
2. Knowles TP. et al. An analytical solution to the kinetics of breakable filament assembly. Science 326, 1533-1537 (2009).
3. Jellinger KA. Formation and development of Lewy pathology: A critical update. J Neurol 256, 270-279 (2009).
4. Rao K. Thermodynamics imprinting reveals differential binding of metals to ?-synuclein: Relevance to parkinson's disease. Biochem Biophys Res Commun 359, 115-120 (2007).
5. Danzer KM et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener 7, 42 (2012).
6. Winner B. et al. In vivo demonstration that ?-synuclein oligomers are toxic. Proc Natl Acad Sci 108, 4194-4199 (2011).
7. Jellinger KA. Interaction between alpha-Synuclein and Other Proteins in Neurodegenerative Disorders. Scientific World J 11, 1893-1907 (2011).
8. Gruden MA. et al. Intranasal administration of alpha-synuclein aggregates: A Parkinson's disease model with behavioral and neurochemical correlates. Behav Brain Res 263, 158-168 (2014).
9. Hong D-P., Fink AL. & Uversky VN. Smoking and Parkinson's disease: Does nicotine affect ?-synuclein fibrillation? BBAProteins Proteom 1794, 282-290 (2009).
10. Rekas A. et al. The structure of dopamine induced ?-synuclein oligomers. Eur Biophys J 39, 1407-1419 (2010).
11. Falsone SF. et al. The neurotransmitter serotonin interrupts ?-synuclein amyloid maturation. BBA-Proteins Proteom 1814, 553-561 (2011).
12. Horvath I. et al. Mechanisms of protein oligomerization: Inhibitor of functional amyloids templates ?-synuclein fibrillation. J Am Chem Soc 134, 3439-3444 (2012).
13. Cegelski L. et al. Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation. Nat Chem Biol 5, 913-919 (2009).
14. Horvath I. et al. Modulation of ?-synuclein fibrillization by ring-fused 2-pyridones: Templation and inhibition involve oligomers with different structure. Arch Biochem Biophys 532, 84-90 (2013).
15. Giehm L., Svergun DI., Otzen DE. & Vestergaard B. Low-resolution structure of a vesicle disrupting ?-synuclein oligomer that accumulates during fibrillation. Proc Natl Acad Sci 108, 3246-3251 (2011).
16. Lorenzen N. et al. The role of stable ?-synuclein oligomers in the molecular events underlying amyloid formation. J Am Chem Soc 136, 3859-3868 (2014).
17. Kelly SM., Jess TJ. & Price NC. How to study proteins by circular dichroism. BBA-Proteins Proteom 1751, 119-139 (2005).
18. Van Maarschalkerweerd A., et al. Protein/lipid coaggregates are formed during ?-synuclein-induced disruption of lipid bilayers. Bio Mac 15, 3643-3654 (2014).
19. Giehm L., Lorenzen N. & Otzen DE. Assays for ?-synuclein aggregation. Meths 53, 295-305 (2011).
20. Xue W-F. et al. Fibril fragmentation enhances amyloid cytotoxicity. J Biol Chem 284, 34272-34282 (2009).
21. Nielsen SB. et al. Wildtype and A30P mutant alpha-synuclein form different fibril structures. PLoS One 8, e67713 (2013).
22. Petoukhov MV. et al. New developments in the ATSAS program package for small-angle scattering data analysis. J Appl Crystallogr 45, 342-350 (2012).
23. Vestergaard B. et al. A helical structural nucleus is the primary elongating unit of insulin amyloid fibrils. PLoS Biol 5, e134 (2007).
24. Svergun D. Restoring low resolution structure of biological macromolecules from solution scattering using simulated annealing. Biophys J 76, 2879-2886 (1999).
25. Foderà V., Zaccone A., Lattuada M. & Donald AM. Electrostatics controls the formation of amyloid superstructures in protein aggregation. Phys Rev Lett 111, 108105 (2013).
26. Huang C., Ren G., Zhou H. & Wang C-c. A new method for purification of recombinant human ?-synuclein in Escherichia coli. Protein Expression Purif 42, 173-177 (2005).
27. Rambo RP. & Tainer JA. Accurate assessment of mass, models and resolution by small-angle scattering. Nature 496, 477-481 (2013).
28. Svergun D. Determination of the regularization parameter in indirect-transform methods using perceptual criteria. J Appl Crystallogr 25, 495-503 (1992).
29. Volkov VV. & Svergun DI. Uniqueness of ab initio shape determination in small-angle scattering. J Appl Crystallogr 36, 860-864 (2003).
30. Smith MI. et al. Factors affecting the formation of insulin amyloid spherulites. Colloids Surf B Biointerfaces 89, 216-222 (2012).
31. Sumner Makin O., Sikorski P. & Serpell LC. CLEARER: A new tool for the analysis of X-ray fibre diffraction patterns and diffraction simulation from atomic structural models. J Appl Crystallogr 40, 966-972 (2007).